


In the Claims

Please amend the claims according to the claim listing provided below.

1. (original) A compound of Formula (Ia):



wherein:

R₂ is H, halogen, C₁₋₁₂ alkyl or C₁₋₁₂ haloalkyl; and

R₃ is C₃₋₆ cycloalkyl, C₁₋₁₂ alkyl, C₁₋₁₂ haloalkyl, C₃₋₆ cycloalkyl-C₁₋₄-alkylene, aryl-C₁₋₄-alkylene or heteroaryl-C₁₋₄-alkylene, wherein said aryl-C₁₋₄-alkylene and heteroaryl-C₁₋₄-alkylene can be optionally substituted with 1 to 5 substituents selected from the group consisting of C₁₋₄ acyl, C₁₋₄ acyloxy, C₂₋₄ alkenyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, C₁₋₄ alkylcarboxamide, C₂₋₄ alkynyl, C₁₋₄ alkylsulfonamide, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylthio, C₁₋₄ alkylureyl, amino, C₁₋₄ alkylamino, C₁₋₄ dialkylamino, arylsulfonyl, carbo-C₁₋₄-alkoxy, carboxamide, carboxy, cyano, C₃₋₆ cycloalkyl, C₁₋₄ dialkylcarboxamide, C₁₋₄ dialkylsulfonamide, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkylsulfinyl, C₁₋₄ haloalkylsulfonyl, C₁₋₄ haloalkylthio, heterocyclyl, hydroxyl, thio, nitro, C₄₋₆ oxo-cycloalkyl, sulfonamide and sulfonic acid; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that:

- A) if R₂ is H, then R₃ is not CF₃, *n*-propyl, *iso*-butyl, *n*-butyl, *iso*-propyl, *t*-butyl, methyl, ethyl, *n*-pentyl, *n*-hexyl, *n*-heptyl, *n*-nonyl, *n*-undecyl, *n*-dodecyl, cyclopentyl, benzyl, 4-methyl-benzyl, 4-chloro-benzyl, 4-methoxy-benzyl, 3-chloro-benzyl, phenethyl, or 3-phenyl-propyl;
- B) if R₂ is Cl, then R₃ is not *iso*-butyl, ethyl, or CH₃;
- C) if R₂ is Br, then R₃ is not *iso*-butyl, *t*-butyl, or CH₃;
- D) if R₂ is I, then R₃ is not CH₃;
- E) if R₂ is CH₃, then R₃ is not CH₃; and
- F) if R₂ is CF₃, then R₃ is not CF₃.

2. (original) A compound according to claim 1 wherein R_2 is H.
3. (original) A compound according to claim 1 wherein R_2 is halogen.
4. (original) A compound according to claim 3 wherein R_2 is F.
5. (original) A compound according to claim 1 wherein R_2 is C_{1-12} alkyl.
6. (original) A compound according to claim 5 wherein R_2 is selected from the group consisting of $-CH_3$, $-CH_2CH_3$, $-(CH_2)_2CH_3$, $-(CH_2)_3CH_3$, $-(CH_2)_4CH_3$, and $-(CH_2)_5CH_3$.
7. (cancelled)
8. (original) A compound according to claim 1 wherein R_2 is C_{1-12} haloalkyl.
9. (currently amended) A compound according to claim 8 wherein R_2 is the haloalkyl selected from the group consisting of $-CHF_2$, $-CH_2F$, $-CF_3$, $-CF_2CF_3$, $-CH_2CF_3$, $-CH_2CHF_2$, $-CH_2CH_2F$, $-CHFCH_2F$, $-CHFCHF_2$, $-CHFCH_2F$, $-CF_2CHF_2$ and $-CF_2CH_2F$.
10. (cancelled)
11. (cancelled)
12. (currently amended) A compound according to ~~any one of claims 1 to 11~~ claim 1 wherein R_3 is C_{1-12} alkyl.
13. (original) A compound according to claim 12 wherein R_3 is selected from the group consisting of $-CH_3$, $-CH_2CH_3$, $-(CH_2)_2CH_3$, $-(CH_2)_3CH_3$, $-(CH_2)_4CH_3$, $-(CH_2)_5CH_3$, $-(CH_2)_6CH_3$, $-(CH_2)_7CH_3$, $-(CH_2)_8CH_3$, $-(CH_2)_9CH_3$, $-(CH_2)_{10}CH_3$, and $-(CH_2)_{11}CH_3$.
14. (cancelled)


15. (currently amended) A compound according to ~~any one of claims 1 to 11~~ claim 1 wherein R₃ is C₁₋₁₂ haloalkyl.
16. (currently amended) A compound according to claim 15 wherein R₃ is C₁₋₁₂ haloalkyl selected from the group consisting of -CF₃, -CF₂CF₃, -(CF₂)₂CF₃, -CHF₂, -CH₂F, -CH₂CF₃, -CH₂CHF₂, -CF₂CH₃, -CH₂CH₂CF₃, -CH₂CF₂CH₃, -CH₂CF₂CF₃, -CH₂CH₂CH₂CHF₂, and -CH₂CH₂CF₂CH₃.
17. (cancelled)
18. (currently amended) A compound according to ~~any one of claims 1 to 11~~ claim 1 wherein R₃ is C₃₋₆ cycloalkyl.
19. (original) A compound according to claim 18 wherein R₃ is cyclopropyl.
20. (currently amended) A compound according to ~~any one of claims 1 to 11~~ claim 1 wherein R₃ is C₃₋₆ cycloalkyl-C₁₋₄-alkylene optionally substituted with 1 to 5 substituents selected from the group consisting of C₁₋₄ alkoxy, C₁₋₄ alkyl, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylthio, carboxamide, carboxy, cyano, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkylsulfonyl, C₁₋₄ haloalkylthio, hydroxyl, thio, nitro, and sulfonamide.
21. (cancelled)
22. (original) A compound according to claim 20 wherein said C₃₋₆ cycloalkyl-C₁₋₄-alkylene is cyclopropylmethyl.
23. (currently amended) A compound according to ~~any one of claims 1 to 11~~ claim 1 wherein R₃ is aryl-C₁₋₄-alkylene optionally substituted with 1 to 5 substituents selected from the group consisting of C₁₋₄ alkoxy, C₁₋₄ alkyl, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylthio, carboxamide, carboxy, cyano, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkylsulfonyl, C₁₋₄ haloalkylthio, hydroxyl, thio, nitro, and sulfonamide.

24. (original) A compound according to claim 23 wherein said aryl-C₁₋₄-alkylene is selected from the group consisting of benzyl, phenethyl, 1-phenyl-ethyl, 3-phenyl-propyl, 2-phenyl-propyl, 1-phenyl-propyl, 1-phenyl-1-methyl-ethyl, 2-phenyl-1-methyl-ethyl, and 2-phenyl-propyl.
25. (cancelled)
26. (currently amended) A compound according to ~~any one of claims 1 to 11~~ claim 1 wherein R₃ is heteroaryl-C₁₋₄-alkylene optionally substituted with 1 to 5 substituents selected from the group consisting of C₁₋₄ alkoxy, C₁₋₄ alkyl, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylthio, carboxamide, carboxy, cyano, halogen, C₁₋₄ haloalkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkylsulfonyl, C₁₋₄ haloalkylthio, hydroxyl, thio, nitro, and sulfonamide.
27. (original) A compound according to claim 26 wherein said heteroaryl-C₁₋₄-alkylene is selected from the group consisting of thiophen-2-yl-methyl, thiophen-3-yl-methyl, pyrrol-1-yl-methyl, pyrrol-2-yl-methyl, pyrrol-3-yl-methyl, furan-2-yl-methyl, furan-3-yl-methyl, 2-thiophen-2-yl-ethyl, 2-thiophen-3-yl-ethyl, 2-furan-2-yl-ethyl, 2-furan-3-yl-ethyl, 2-pyrrol-1-yl-ethyl, 2-pyrrol-2-yl-ethyl, and 2-pyrrol-3-yl-ethyl.
28. (cancelled)
29. (original) A compound according to claim 1 wherein said compound is selected from the group consisting of:
- 5-Difluoromethyl-2H-pyrazole-3-carboxylic acid;
 - 5-(2,2-Difluoro-ethyl)-2H-pyrazole-3-carboxylic acid;
 - 5-(1,1-Difluoro-ethyl)-2H-pyrazole-3-carboxylic acid;
 - 5-(2,2,-Difluoro-propyl)-2H-pyrazole-3-carboxylic acid;
 - 5-(4,4-Difluoro-butyl)-2H-pyrazole-3-carboxylic acid;
 - 5-(3,3-Difluoro-butyl)-2H-pyrazole-3-carboxylic acid;
 - 5-Cyclopropyl-2H-pyrazole-3-carboxylic acid;
 - 5-Cyclopropylmethyl-2H-pyrazole-3-carboxylic acid;
 - 4-Fluoro-5-methyl-2H-pyrazole-3-carboxylic acid;
 - 5-Difluoromethyl-4-fluoro-2H-pyrazole-3-carboxylic acid;

5-(2,2-Difluoro-ethyl)-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
5-(1,1-Difluoro-ethyl)-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
5-(2,2-Difluoro-propyl)-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
5-Ethyl-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
4-Fluoro-5-propyl-2*H*-pyrazole-3-carboxylic acid;
5-Butyl-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
4-Fluoro-5-pentyl-2*H*-pyrazole-3-carboxylic acid;
4-Fluoro-5-hexyl-2*H*-pyrazole-3-carboxylic acid;
4-Fluoro-5-heptyl-2*H*-pyrazole-3-carboxylic acid;
4-Fluoro-5-octyl-2*H*-pyrazole-3-carboxylic acid;
4-Fluoro-5-nonyl-2*H*-pyrazole-3-carboxylic acid;
5-Decyl-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
4-Fluoro-5-undecyl-2*H*-pyrazole-3-carboxylic acid;
5-Dodecyl-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
5-Cyclopropyl-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
5-Cyclopropylmethyl-4-fluoro-2*H*-pyrazole-3-carboxylic acid;
5-(3-Fluoro-benzyl)-2*H*-pyrazole-3-carboxylic acid;
5-(3-Bromo-benzyl)-2*H*-pyrazole-3-carboxylic acid;
5-(4-Bromo-benzyl)-2*H*-pyrazole-3-carboxylic acid; and
5-[2-(4-Methoxy-phenyl)-ethyl]-2*H*-pyrazole-3-carboxylic acid.

30. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 29~~ to claim 1 in combination with a pharmaceutically acceptable carrier.
31. (cancelled)
32. (cancelled)
33. (cancelled)
34. (cancelled)

35. (cancelled)
36. (cancelled)
37. (currently amended) A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically-effective amount of a compound according to ~~any one of claims 1 to 29~~ to claim 1.
38. (original) A method according to claim 37 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
39. (original) A method according to claim 37 wherein said metabolic-related disorder is atherosclerosis.
40. (cancelled)
41. (cancelled)
42. (cancelled)
43. (new) A compound according to claim 1 having Formula (II):



or a pharmaceutically acceptable salt, solvate or hydrate thereof;

wherein:

R₂ is F;

R₃ is selected from the group consisting of cyclopropyl, cyclopropylmethyl, 2-cyclopropyl-ethyl, -CH₃, -CH₂CH₃, -(CH₂)₂CH₃, -(CH₂)₃CH₃, -CHF₂, -CH₂F, -CH₂CF₃, -CF₃, -CH₂CHF₂, -CF₂CF₃, -CF₂CH₃, -CH₂CH₂CF₃, -CH₂CF₂CH₃, -CH₂CF₂CF₃, -(CF₂)₂CF₃, -CH₂CH₂CH₂CHF₂, and -CH₂CH₂CF₂CH₃; and

R_4 is selected from the group consisting of H, $-CH_3$, $-CH_2CH_3$, $-(CH_2)_2CH_3$, $-(CH_2)_3CH_3$, $-(CH_2)_4CH_3$, $-(CH_2)_5CH_3$, and $-(CH_2)_6CH_3$.

44. (new) A method of raising HDL in an individual comprising administering to an individual in need of such treatment a therapeutically-effective amount of a compound according to claim 1.
45. (new) A method of lowering LDL in an individual comprising administering to an individual in need of such treatment a therapeutically-effective amount of a compound according to claim 1.